Form 4: ADMA Biologics CFO Brad L. Tade Sells 15,000 Shares Following RSU Vesting

ADMA Biologics CFO and Treasurer, Brad L. Tade, sold 15,000 shares of common stock at $21.15 per share following the vesting of restricted stock units.

Summary

• Brad L. Tade, CFO and Treasurer of ADMA Biologics, sold 15,000 shares of common stock on November 22, 2024, at a price of $21.15 per share.
• The sale occurred after the vesting of restricted stock units (RSUs) that were granted on June 26, 2023, and vested on June 26, 2024.
• Following the transaction, Mr. Tade beneficially owns 199,433 shares of ADMA Biologics common stock.
• This total includes unvested RSUs granted on July 24, 2024, June 26, 2023, and February 26, 2024, as well as shares acquired through open market purchases and RSU vesting.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation. It is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing related to insider transactions and is common for executives who receive stock-based compensation. It does not indicate any specific trend in the industry.

Comparison to Industry Standards

• Executive stock sales following vesting are a common practice across the biotechnology industry.
• Many companies use RSUs as part of their compensation packages, and executives often sell shares to manage their personal finances.
• The sale by Mr. Tade is consistent with typical insider transactions observed in similar companies.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale by an executive.
• The sale does not indicate any change in the company's operations or financial health.

Key Dates

Keywords

ADMA Biologics, Brad L. Tade, CFO, stock sale, restricted stock units, RSU, insider trading, beneficial ownership